Glycosaminoglycans and Glycolipids As Potential Biomarkers in Lung Cancer

Overview

Journal Glycoconj J

Publisher Springer

Specialties Biochemistry
Endocrinology

Date 2017 Aug 20

PMID 28822024

Citations 15

Authors

Guoyun Li

Lingyun Li

Eun Ji Joo

Ji Woong Son

Young Jin Kim

Jae Ku Kang

Kyung Bok Lee

Fuming Zhang

Robert J Linhardt

Affiliations

Soon will be listed here.

Abstract

In this report, we used liquid chromatography-mass spectrometry and Western blotting to analyze the content and structure of glycosaminoglycans, glycolipids and selected proteins to compare differences between patient-matched normal and cancerous lung tissues obtained from lung cancer patients. The cancer tissue samples contained over twice as much chondroitin sulfate (CS)/dermatan sulfate (DS) as did the normal tissue samples, while the amount of heparan sulfate (HS) and hyaluronan (HA) in normal and cancer tissues were not significantly different. In HS, several minor disaccharide components, including NS6S, NS2S and 2S were significantly lower in cancer tissues, while the levels of major disaccharides, TriS, NS and 0S disaccharides were not significantly different in normal and cancer tissues. In regards to CS/DS, the level of 4S disaccharide (the major component of CS-type A and DS) decreased and the level of 6S disaccharide (the major component of CS- type C) increased in cancer tissues. We also compared the content and structure of GAGs in lung tissues from smoking and non-smoking patients. Analysis of the glycolipids showed all lipids present in these lung tissues, with the exception of sphingomyelin were higher in cancer tissues than in normal tissues. Western analysis showed that syndecan 1 and 2 proteoglycans displayed much higher expression in cancer tissue/biopsy samples. This investigation begins to provide an understanding of patho-physiological roles on glycosaminoglycans and glycolipids and might be useful in identifying potential biomarkers in lung cancer.

Citing Articles

Targeting nanoparticles to lung cancer-derived A549 cells based on changes on interstitial stiffness in biomimetic models.

Kohon A, Man K, Hessami A, Mathis K, Webb J, Fang J iScience. 2024; 27(10):111015.

PMID: 39435151 PMC: 11492096. DOI: 10.1016/j.isci.2024.111015.

Discriminating Benign from Malignant Lung Diseases Using Plasma Glycosaminoglycans and Cell-Free DNA.

Qvick A, Bratulic S, Carlsson J, Stenmark B, Karlsson C, Nielsen J Int J Mol Sci. 2024; 25(18).

PMID: 39337265 PMC: 11431521. DOI: 10.3390/ijms25189777.

Biomarkers in Cancer Detection, Diagnosis, and Prognosis.

Das S, Dey M, Devireddy R, Gartia M Sensors (Basel). 2024; 24(1).

PMID: 38202898 PMC: 10780704. DOI: 10.3390/s24010037.

Compositional Analysis of Glycosaminoglycans in Different Lung Cancer Types-A Pilot Study.

Pal D, Toth G, Sugar S, Fugedi K, Szabo D, Kovalszky I Int J Mol Sci. 2023; 24(8).

PMID: 37108213 PMC: 10138872. DOI: 10.3390/ijms24087050.

Inter- and intratumoral proteomics and glycosaminoglycan characterization of ALK rearranged lung adenocarcinoma tissues: a pilot study.

Balbisi M, Sugar S, Schlosser G, Szeitz B, Fillinger J, Moldvay J Sci Rep. 2023; 13(1):6268.

PMID: 37069213 PMC: 10110559. DOI: 10.1038/s41598-023-33435-1.

References

Shi X, Liang W, Yang W, Xia R, Song Y . Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol. 2014; 36(5):3345-54. DOI: 10.1007/s13277-014-2968-8. View

Yang B, Chang Y, Weyers A, Sterner E, Linhardt R . Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J Chromatogr A. 2012; 1225:91-8. PMC: 3268819. DOI: 10.1016/j.chroma.2011.12.063. View

Yeat N, Lin C, Sager M, Lin J . Cancer proteomics: developments in technology, clinical use and commercialization. Expert Rev Proteomics. 2015; 12(4):391-405. DOI: 10.1586/14789450.2015.1051969. View

Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y . Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int J Oncol. 2008; 33(6):1177-85. View

Couchman J, Pataki C . An introduction to proteoglycans and their localization. J Histochem Cytochem. 2012; 60(12):885-97. PMC: 3527888. DOI: 10.1369/0022155412464638. View

Farnedi A, Rossi S, Bertani N, Gulli M, Silini E, Mucignat M . Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors. BMC Cancer. 2015; 15:352. PMC: 4429505. DOI: 10.1186/s12885-015-1336-4. View

Weyers A, Yang B, Yoon D, Park J, Zhang F, Lee K . A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?. OMICS. 2012; 16(3):79-89. PMC: 3300064. DOI: 10.1089/omi.2011.0102. View

Zhao Z, Han C, Liu J, Wang C, Wang Y, Cheng L . GPC5, a tumor suppressor, is regulated by miR-620 in lung adenocarcinoma. Mol Med Rep. 2014; 9(6):2540-6. DOI: 10.3892/mmr.2014.2092. View

Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M . Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci. 2012; 104(1):43-7. PMC: 7657197. DOI: 10.1111/cas.12027. View

10.

Lemjabbar-Alaoui H, McKinney A, Yang Y, Tran V, Phillips J . Glycosylation alterations in lung and brain cancer. Adv Cancer Res. 2015; 126:305-44. PMC: 6080207. DOI: 10.1016/bs.acr.2014.11.007. View

11.

Timek D, Shi J, Liu H, Lin F . Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012; 138(2):203-10. DOI: 10.1309/AJCPK1ZC9WNHCCMU. View

12.

Yang X, Zhang Z, Qiu M, Hu J, Fan X, Wang J . Glypican-5 is a novel metastasis suppressor gene in non-small cell lung cancer. Cancer Lett. 2013; 341(2):265-73. DOI: 10.1016/j.canlet.2013.08.020. View

13.

Kumar S, Lanckacker E, Dentener M, Bracke K, Provoost S, De Grove K . Aggravation of Allergic Airway Inflammation by Cigarette Smoke in Mice Is CD44-Dependent. PLoS One. 2016; 11(3):e0151113. PMC: 4801229. DOI: 10.1371/journal.pone.0151113. View

14.

Li W, Zhao K, Kirberger M, Liao W, Yan Y . Next generation sequencing technologies in cancer diagnostics and therapeutics: A mini review. Cell Mol Biol (Noisy-le-grand). 2015; 61(5):91-102. View

15.

Hakomori S . Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res. 1989; 52:257-331. DOI: 10.1016/s0065-230x(08)60215-8. View

16.

Kim H, Xu G, Borczuk A, Busch S, Filmus J, Capurro M . The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol. 2003; 29(6):694-701. DOI: 10.1165/rcmb.2003-0061OC. View

17.

Joo E, Weyers A, Li G, Gasimli L, Li L, Choi W . Carbohydrate-containing molecules as potential biomarkers in colon cancer. OMICS. 2014; 18(4):231-41. PMC: 3976574. DOI: 10.1089/omi.2013.0128. View

18.

Mujoo K, Cheresh D, Yang H, Reisfeld R . Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987; 47(4):1098-104. View

19.

Ucakturk E, Akman O, Sun X, Baydar D, Dolgun A, Zhang F . Changes in composition and sulfation patterns of glycoaminoglycans in renal cell carcinoma. Glycoconj J. 2015; 33(1):103-12. DOI: 10.1007/s10719-015-9643-1. View

20.

Chen J, Repunte-Canonigo V, Kawamura T, Lefebvre C, Shin W, Howell L . Hypothalamic proteoglycan syndecan-3 is a novel cocaine addiction resilience factor. Nat Commun. 2013; 4:1955. PMC: 3709481. DOI: 10.1038/ncomms2955. View